🔴 Painreform is trading 6% down as biotech weakness offers partial context

Painreform is trading at $0.78 (-6.01%) as biotech-sector weakness is the likeliest available context, though it does not fully explain the decline.

• No new company-specific announcement explaining the decline was identified; Painreform’s investor-relations page lists September 16, 2026, as its latest press release.
• The supplied context shows biotech ETF XBI down 2.06%, alongside broader risk-off pressure.